Xeris Pharmaceuticals Inc Asset Resilience Ratio
Xeris Pharmaceuticals Inc asset resilience ratio. Xeris Pharmaceuticals Inc (XERS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See XERS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xeris Pharmaceuticals Inc (2018–2024)
Asset resilience ratio of Xeris Pharmaceuticals Inc from 2018 to 2024. This chart shows how Xeris Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read how much debt does Xeris Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xeris Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Xeris Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Xeris Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Xeris Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Xeris Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Xeris Pharmaceuticals Inc Asset Resilience Ratio by Year (2018–2024)
Xeris Pharmaceuticals Inc asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for Xeris Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $323.06 Million | -- |
| 2023-12-31 | 1.55% | $5.00 Million | $322.60 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $344.52 Million | -- |
| 2021-12-31 | 11.55% | $35.16 Million | $304.36 Million | -39.86pp |
| 2020-12-31 | 51.41% | $56.03 Million | $108.99 Million | 0.00pp |
| 2019-12-31 | 51.41% | $56.03 Million | $108.99 Million | -4.34pp |
| 2018-12-31 | 55.75% | $66.92 Million | $120.03 Million | -- |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more